Refine
Year of publication
Document Type
- Article (30)
- Preprint (2)
- Conference Proceeding (1)
- Doctoral Thesis (1)
Has Fulltext
- yes (34)
Is part of the Bibliography
- no (34)
Keywords
- Cell biology (2)
- Cryoelectron microscopy (2)
- Research article (2)
- Superficial vein thrombosis (2)
- homeostasis (2)
- rat (2)
- synaptic scaling (2)
- Bacterial structural biology (1)
- Biochemistry (1)
- Bioenergetics (1)
Institute
The neutron capture cross section of 58Ni was measured at the neutron time of flight facility n_TOF at CERN, from 27 meV to 400 keV neutron energy. Special care has been taken to identify all the possible sources of background, with the so-called neutron background obtained for the first time using high-precision GEANT4 simulations. The energy range up to 122 keV was treated as the resolved resonance region, where 51 resonances were identified and analyzed by a multilevel R-matrix code SAMMY. Above 122 keV the code SESH was used in analyzing the unresolved resonance region of the capture yield. Maxwellian averaged cross sections were calculated in the temperature range of kT = 5 – 100 keV, and their astrophysical implications were investigated.
In homeostatic scaling at central synapses, the depth and breadth of cellular mechanisms that detect the offset from the set-point, detect the duration of the offset and implement a cellular response are not well understood. To understand the time-dependent scaling dynamics we treated cultured rat hippocampal cells with either TTX or bicucculline for 2 hr to induce the process of up- or down-scaling, respectively. During the activity manipulation we metabolically labeled newly synthesized proteins using BONCAT. We identified 168 newly synthesized proteins that exhibited significant changes in expression. To obtain a temporal trajectory of the response, we compared the proteins synthesized within 2 hr or 24 hr of the activity manipulation. Surprisingly, there was little overlap in the significantly regulated newly synthesized proteins identified in the early- and integrated late response datasets. There was, however, overlap in the functional categories that are modulated early and late. These data indicate that within protein function groups, different proteomic choices can be made to effect early and late homeostatic responses that detect the duration and polarity of the activity manipulation.
In der vorliegenden Arbeit wurde die zelluläre Verteilung der beiden Ekto-Nukleotidasen TNAP (gewebeunspezifische Form der alkalischen Phosphatase) und NTPDase2 (Nukleosidtriphosphatdiphosphohydrolase) in den embryonalen, postnatalen und adulten neurogenen Zonen des Mäusehirns untersucht.
• Mittels enzym- und immunhistochemischer Markierungen wurde die TNAP erstmals auf den Zellen der SVZ (subventrikuläre Zone) und des RMS (rostraler Migrationsstrom) nachgewiesen.
• Immunhistochemische Doppelfärbungen von Gewebeschnitten und von akut isolierten Zellen aus der SVZ adulter und postnataler (P15) Mäuse zeigten, dass die TNAP von allen drei Typen neuronaler Vorläuferzellen (Typ B-, C- und A-Zellen) der SVZ exprimiert wird.
• Enzymatische Markierungen verschiedener Embryonal- und Postnatalstadien (ab Embryonalstadium14, E14) ergaben, dass die TNAP schon im Stadium E 14 im Bereich der Seitenventrikel exprimiert wird:
o In den frühen Embryonalstadien lag die TNAP über die gesamte Gewebedicke, von der ventrikulären bis zur pialen Oberfläche vor.
o Im Laufe der weiteren Entwicklung war eine im Kortex beginnende und sich später bis in das Striatum ausweitende Reduktion der TNAP-Aktivität zu beobachten. Mit zunehmender Reifung des Gehirns wurde die Schicht der TNAP-positiven Zellen dünner und beschränkte sich schließlich auf die SVZ.
• Die NTPDase2 war erst im Zeitraum zwischen E18 und P2 nachweisbar. Sie war im Bereich der Seitenventrikel lokalisiert und auf die an die Ventrikel angrenzenden Zellen beschränkt. Im Laufe der weiteren Entwicklung wandern die NTPDase2-positiven Zellen offensichtlich in die SVZ ein und ab P14 waren sie zu hüllartigen Strukturen angeordnet, die eine Doppelmarkierung für TNAP und NTPDase2 aufwiesen und Gruppen DCX-positiver Zellen (Typ-A Zellen, Neuroblasten) umschlossen.
• Die Markierung mit dem Neuroblastenmarker DCX war bereits zum Stadium E14 möglich. In diesem Altersstadium wurden lediglich die Zellen im Bereich des Kortex gefärbt. Im Laufe der postnatalen Entwicklung verlagerten sich die DCX-positiven Zellen ihren Schwerpunkt in den Bereich der SVZ. Bereits ab P10 lagen in der SVZ Gruppen von DCX/TNAP-doppelpositiven Zellen vor, Anzeichen für eine Konzentrierung der Neurogenese auf die SVZ.
• Die Ausschaltung des TNAP-Gens (TNAP-Knockout-Mäuse) hatte keinen offensichtlichen Einfluss auf die Ausbildung der Seitenventrikel oder die Ausbildung und zelluläre Zusammensetzung der SVZ.
• In der zweiten wesentlichen neurogenen Zone des Säugerhirns, dem Gyrus dentatus des Hippokampus, konnte die TNAP nicht nachgewiesen werden, obwohl die dortigen Vorläuferzellen NTPDase2 exprimieren.
Die vorliegenden Daten belegen erstmals eine Assoziation der TNAP mit neuronalen Vorläuferzellen und erlauben zusammen mit den Markierungen für NTPDase2 und weitere zelluläre Marker neue Einsichten in die zelluläre Entwicklung der adulten SVZ. Darüber hinaus stützen sie die Vorstellung einer Beteilung purinerger Signalwege an der Steuerung der embryonalen, postnatalen und adulten Neurogenese.
Understanding the conformational sampling of translation-arrested ribosome nascent chain complexes is key to understand co-translational folding. Up to now, coupling of cysteine oxidation, disulfide bond formation and structure formation in nascent chains has remained elusive. Here, we investigate the eye-lens protein γB-crystallin in the ribosomal exit tunnel. Using mass spectrometry, theoretical simulations, dynamic nuclear polarization-enhanced solid-state nuclear magnetic resonance and cryo-electron microscopy, we show that thiol groups of cysteine residues undergo S-glutathionylation and S-nitrosylation and form non-native disulfide bonds. Thus, covalent modification chemistry occurs already prior to nascent chain release as the ribosome exit tunnel provides sufficient space even for disulfide bond formation which can guide protein folding.
Ribosomes translate the genetic code into proteins. Recent technical advances have facilitated in situ structural analyses of ribosome functional states inside eukaryotic cells and the minimal bacterium Mycoplasma. However, such analyses of Gram-negative bacteria are lacking, despite their ribosomes being major antimicrobial drug targets. Here we compare two E. coli strains, a lab E. coli K-12 and human gut isolate E. coli ED1a, for which tetracycline exhibits bacteriostatic and bactericidal action, respectively. The in situ ribosome structures upon tetracycline treatment show a virtually identical drug binding-site in both strains, yet the distribution of ribosomal complexes clearly differs. While K-12 retains ribosomes in a translation competent state, tRNAs are lost in the vast majority of ED1a ribosomes. A differential response is also reflected in proteome-wide abundance and thermal stability assessment. Our study underlines the need to include molecular analyses and to consider gut bacteria when addressing antibiotic mode of action.
We measured the Coulomb dissociation of 16O into 4He and 12C at the R3B setup in a first campaign within FAIR Phase 0 at GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt. The goal was to improve the accuracy of the experimental data for the 12C(α,γ)16O fusion reaction and to reach lower center-ofmass energies than measured so far.
The experiment required beam intensities of 109 16O ions per second at an energy of 500 MeV/nucleon. The rare case of Coulomb breakup into 12C and 4He posed another challenge: The magnetic rigidities of the particles are so close because of the same mass-to-charge-number ratio A/Z = 2 for 16O, 12C and 4He. Hence, radical changes of the R3B setup were necessary. All detectors had slits to allow the passage of the unreacted 16O ions, while 4He and 12C would hit the detectors' active areas depending on the scattering angle and their relative energies. We developed and built detectors based on organic scintillators to track and identify the reaction products with sufficient precision.
Dimerization of Taspase1 activates an intrinsic serine protease function that leads to the catalytic Thr234 residue, which allows to catalyze the consensus sequence Q−3X−2D−1⋅G1X2D3D4, present in Trithorax family members and TFIIA. Noteworthy, Taspase1 performs only a single hydrolytic step on substrate proteins, which makes it impossible to screen for inhibitors in a classical screening approach. Here, we report the development of an HTRF reporter assay that allowed the identification of an inhibitor, Closantel sodium, that inhibits Taspase1 in a noncovalent fashion (IC50 = 1.6 μM). The novel inhibitor interferes with the dimerization step and/or the intrinsic serine protease function of the proenzyme. Of interest, Taspase1 is required to activate the oncogenic functions of the leukemogenic AF4-MLL fusion protein and was shown in several studies to be overexpressed in many solid tumors. Therefore, the inhibitor may be useful for further validation of Taspase1 as a target for cancer therapy.
New neutron cross section measurements of minor actinides have been performed recently in order to reduce the uncertainties in the evaluated data, which is important for the design of advanced nuclear reactors and, in particular, for determining their performance in the transmutation of nuclear waste. We have measured the 241Am(n,γ) cross section at the n_TOF facility between 0.2 eV and 10 keV with a BaF2 Total Absorption Calorimeter, and the analysis of the measurement has been recently concluded. Our results are in reasonable agreement below 20 eV with the ones published by C. Lampoudis et al. in 2013, who reported a 22% larger capture cross section up to 110 eV compared to experimental and evaluated data published before. Our results also indicate that the 241Am(n,γ) cross section is underestimated in the present evaluated libraries between 20 eV and 2 keV by 25%, on average, and up to 35% for certain evaluations and energy ranges.
The accuracy on neutron capture cross section of fissile isotopes must be improved for the design of future nuclear systems such as Gen-IV reactors and Accelerator Driven Systems. The High Priority Request List of the Nuclear Energy Agency, which lists the most important nuclear data requirements, includes also the neutron capture cross sections of fissile isotopes such as 233,235U and 239,241Pu. A specific experimental setup has been used at the CERN n_TOF facility for the measurement of the neutron capture cross section of 235U by a set of micromegas fission detectors placed inside a segmented BaF2 Total Absorption Calorimeter.
Objective: Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions.
Methods: Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding.
Results: A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was below the knee in 54.5%, above the knee in 26.7%, above and below the knee in 18.8%. At baseline, 93.6% received pharmacological treatment (65.7% fondaparinux, 23.2% heparins, 4.3% direct oral anticoagulants [DOACs], 14.5% analgesics), 77.0% compression treatment, and 1.9% surgery; 6.4% did not receive any anticoagulation. The primary outcome occurred in 5.8%; 4.7% had recurrent or extended SVT, 1.7% DVT, and 0.8% PE. Clinically relevant non-major bleeding occurred in 1.2% and major bleeding in 0.3%. Complete clinical recovery of SVT was reported in 708 patients (62.4%). Primary outcome adjusted by propensity score and for treatment duration was lower with fondaparinux compared with low molecular weight heparin (4.4% vs. 9.6%; hazard ratio [HR] 0.51; 95% confidence interval [CI] 0.3 - 0.9; p = .017). On multivariable analysis, associated factors for primary outcome included another SVT prior to the present SVT event (HR 2.3), age per year (HR 0.97), duration of drug treatment per week (HR 0.92), and thrombus length (HR 1.03).
Conclusion: At three month follow up, patients with isolated SVT are at risk of thromboembolic complications (mainly recurrent or extended SVT), despite anticoagulation. In this real life study, about one third had received either heparins, oral anticoagulants, or no anticoagulation.